by Coinstrooper Crypto Articles
Quick Take
  • The hantavirus outbreak on the MV Hondius lifted one mRNA leader 36% off May lows before profit-taking trimmed the rally.
  • The brief move reactivated the pandemic-prep trade across medical stocks, putting three Covid-era stocks back on the 2026 comeback watchlist.
  • One name has already moved on to the mRNA platform strength.
  • Another builds an inverse base as the biodefense contractor.

What Happened

The hantavirus outbreak on the MV Hondius lifted one mRNA leader 36% off May lows before profit-taking trimmed the rally. The brief move reactivated the pandemic-prep trade across medical stocks, putting three Covid-era stocks back on the 2026 comeback watchlist.

Market Context

Among the Covid-era stocks rotating back into focus, Moderna stock rallied 36.08% from $43.69 on May 1 to $59.45 on May 11. Volume rose alongside price throughout the climb, confirming buying pressure rather than short covering.

Moderna’s price now sits near $54.05, consolidating in what resembles the handle of a cup-and-handle continuation pattern. The cup bottom anchors at $43.69, and the rim sits near $59.45.

The handle is forming above the 20-day Exponential Moving Average (EMA), a trend indicator that weights recent price action more heavily, currently at $50.50.

A daily close above $10.02, which aligns with the neckline and the 0.786 Fibonacci level, confirms the breakout. The measured move projects 25.76% upside toward $12.65, with the prior high at $14.07 capping the extended target.

Why It Matters

Each setup carries a different signal. One name has already moved on to the mRNA platform strength. Another builds an inverse base as the biodefense contractor. The third offers a contrarian play loaded with bears. May 2026 is when each chart picks a side.

That second dip created the head of an inverse head-and-shoulders pattern. The left shoulder formed near $7.82 in late March. The head dipped to $7.53 in early May. The right shoulder is now forming at $8.33 with visibly weaker selling pressure. That weakening pressure suggests the de-rating may have exhausted.

Details

Note: mRNA, short for messenger RNA, is the vaccine platform behind the COVID-19 shots, delivering genetic instructions to cells instead of using a live virus.

Moderna (NASDAQ: MRNA)

Want more insights like this? Sign up for Editor Harsh Notariya’s Daily Newsletter here.

Three catalysts drove the move. Q1 2026 revenue grew 260% year-over-year to $389 million; the company disclosed a hantavirus vaccine collaboration with the US Army Medical Research Institute of Infectious Diseases; and Phase 3 mRNA-1010 flu data were published in the New England Journal of Medicine.

Cup-and-handle patterns can fail if the handle retraces deeper than half the cup, which would put the bullish thesis in question.

The pattern stays valid as long as $51.17 holds. A daily close below opens the way to the 20-day EMA at $50.50 and the 50-day EMA at $49.75. A break under $43.69 invalidates the pattern entirely.

A daily close above $54.91 starts the handle breakout. A move above $60.96, which aligns with the upward-sloping neckline and the 0.618 Fibonacci level, confirms the breakout and projects a measured move to $81.46, roughly 33.59% above current levels.

Moderna already took its leg up. A smaller name (EBS) behind the US pandemic stockpile has not.

Emergent BioSolutions (NYSE: EBS)

Among the Covid-era stocks with the steepest drawdowns, Emergent stock manufactured Johnson & Johnson’s COVID-19 vaccine at its Baltimore Bayview facility under a $480 million contract. A 2021 contamination scandal that ruined 15 million doses then triggered a multi-year de-rating.

The stock corrected 44.36% from $14.07 to $7.53 earlier this year. The trigger was Emergent guiding FY26 revenue to $720-760 million on March 1, below consensus.

A second leg followed on April 30, when Q1 2026 revenue fell 30% year-over-year to $156.1 million, driven by weaker sales of anthrax and smallpox medical countermeasures.

Inverse head-and-shoulders patterns fail when the right shoulder dips below the head, which would put the floor in question.

A daily close below $8.33 weakens the structure. A break under $7.53 invalidates the pattern entirely.

Emergent’s pattern is set. The final chart shows the contrarian mRNA name loaded with bear positioning.

BioNTech (NASDAQ: BNTX)

Among the Covid-era stocks with the most direct mRNA platform pedigree, BioNTech co-developed COMIRNATY with Pfizer. The partners delivered 2.6 billion doses across 165 countries in 2021. Peak revenue hit €18.98 billion that year.